Reviewer's report

Title: Clinical pharmacy activities in chronic kidney disease and end-stage renal disease patients: A systematic literature review

Version: 2 Date: 13 May 2011

Reviewer: Thomas Dowling

Reviewer's report:

This paper is a well-written review of literature related to documented clinical pharmacy interventions in patients with kidney disease. However, the text lacks sufficient detail in results to support many statements made by the authors, and is not appropriate to leave results to a supplemental table only. The supplemental tables need to be included in the manuscript, not as separate documents. The authors need to discuss the role of the pharmacist in helping to manage urinary albumin excretion rates during ACE/ARB therapy. Table 4 is too general, needs more detail. There also needs to be more detail regarding the results of studies evaluating a pharmacists role in hypertension and diabetes in patients with CKD (see: Borenstein JE, Graber G, Saltiel E, et al. Physicianpharmacist comanagement of hypertension: a randomized, comparative trial. Pharmacotherapy 2003;23:209–16.)

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

'I declare that I have no competing interests'